RUI KANG PHARMACEUTICAL GROUP INVESTMENTS LIMITED
銳康藥業集團投資有限公司
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock code: 8037)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2016

Reference is made to the annual results announcement of Rui Kang Pharmaceutical Group Investments Limited ("**Company**", together with its subsidiaries, the "**Group**") dated 20 March 2017 ("**2016 Annual Results Announcement**") in respect of the annual results of the Group for the year ended 31 December 2016. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2016 Annual Results Announcement.

Further to the information disclosed in the 2016 Annual Results Announcement, the Company would like to provide the shareholders of the Company and potential investors with the following additional information about the performance of the Group's significant investments:

SIGNIFICANT INVESTMENT HELD AND PERFORMANCE

As at 31 December 2016, the Group's held for trading securities, which were companies listed on the Stock Exchange, amounted to approximately HK$53,844,000 (including its investment in 0.51% issued share capital of Town Health (a listed company principally engaged in the provision of healthcare services) with a fair value of HK$49,785,000 million as at 31 December 2016). For the 2016 Year, the Group received a dividend income of approximately HK$395,000 from this investment and recorded a realised and unrealised loss due to change in fair value of approximately HK$180,000 and HK$13,113,000 respectively.

The Board acknowledges that the performance of equity investment is subject to certain degree of volatility in the Hong Kong stock market and is susceptible to other external factors. It has been the policy of the Company to closely monitor the performance of its securities investment and to diversify the investment portfolio with a view to mitigating possible financial risks related to the equity investment.

GENERAL

The above additional information does not affect other information contained in the 2016 Annual Results Announcement and, save as disclosed in this announcement, the contents of the 2016 Annual Results Announcement remain correct and unchanged.

On behalf of the Board
Rui Kang Pharmaceutical Group Investments Limited
CHAN Ka Chung
Chairman

Hong Kong, 24 March 2017

As of the date of this announcement, the executive Directors are Mr. CHAN Ka Chung (Chairman), Mr. LEUNG Pak Hou Anson, Ms. CHEN Miaoping (Chief Executive Officer) and Mr. CHEUNG Wai Kwan; and the independent non-executive Directors are Mr. HO Fung Shan Bob, Mr. LEUNG Ka Fai and Mr. YUEN Chun Fai.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.ruikang.com.hk.